Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000078303 | SCV000110143 | pathogenic | not provided | 2013-08-30 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001420761 | SCV001623109 | pathogenic | Fabry disease | 2024-02-22 | criteria provided, single submitter | clinical testing | Variant summary: GLA c.959_962delATCA (p.Asn320ArgfsX27) results in a premature termination codon, predicted to cause a truncation of the encoded protein, which is a commonly known mechanism for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory (example: c.994dupA p.Arg332LysfsX7, c.1033_1034delTC p.Ser345ArgfsX29). The variant was absent in 183503 control chromosomes. To our knowledge, no occurrence of c.959_962delATCA in individuals affected with Fabry Disease and no experimental evidence demonstrating its impact on protein function have been reported. ClinVar contains an entry for this variant (Variation ID: 92571). Based on the evidence outlined above, the variant was classified as pathogenic. |
Genome- |
RCV001420761 | SCV002054392 | pathogenic | Fabry disease | 2021-07-15 | criteria provided, single submitter | clinical testing |